Local delivery in the Denver, Colorado area
Are you 21 or older?
The Science Behind Psilocybin Therapy
The Default Mode Network
The Default Mode Network is the part of the brain responsible for self-referential thinking. It drives rumination, self-criticism, and the repetitive negative thought patterns at the root of depression and anxiety. Psilocybin temporarily quiets this network, creating a window where habitual thought patterns lose their grip and new perspectives become accessible. Many people describe it as seeing their life with a clarity they have never experienced before.
Neuroplasticity and Lasting Change
Psilocybin stimulates neuroplasticity, the brain's capacity to form new neural connections. Clinical research suggests it promotes structural and functional growth in areas of the brain that regulate mood and emotional processing. This is why the benefits of a single session can persist for months. It is not simply a temporary chemical effect. The brain is being given the conditions to rewire itself.
Key Studies at a Glance
The following research represents a fraction of the growing clinical evidence supporting psilocybin therapy. All studies referenced were conducted at accredited institutions under rigorous scientific protocols.
| Study | Institution | Year | Key Finding |
|---|---|---|---|
| Psilocybin for Major Depressive Disorder | Johns Hopkins University | 2020 | 71% of participants showed significant reduction in depression symptoms. Over half met criteria for full remission. |
| Psilocybin vs. Escitalopram | Imperial College London | 2022 | Psilocybin produced faster and more robust improvements in emotional well-being compared to a leading SSRI antidepressant. |
| Psilocybin for Cancer-Related Anxiety and Depression | Johns Hopkins and NYU | 2016 | 80% of participants showed clinically significant improvement at six-month follow-up from a single guided session. |
| Psilocybin for Alcohol Use Disorder | Johns Hopkins University | 2022 | Participants showed dramatic improvement in abstinence rates compared to standard treatment approaches. |
| Psilocybin for Tobacco Cessation | Johns Hopkins University | 2014 | 80% of participants significantly reduced or eliminated tobacco use at six-month follow-up, far exceeding standard cessation methods. |
| FDA Breakthrough Therapy Designation | U.S. Food and Drug Administration | 2018 | Psilocybin designated as Breakthrough Therapy for treatment-resistant depression, expediting federal review. |
| FDA Breakthrough Therapy Designation | U.S. Food and Drug Administration | 2019 | Psilocybin received a second Breakthrough Therapy designation for major depressive disorder. |
Psilocybin therapy is no longer on the fringe of medicine. It is being studied, validated, and recognized at the highest levels of clinical research. Colorado's Prop 122 program makes this healing available to you today.
Johns Hopkins — Psilocybin for Major Depression (2021)
A randomized clinical trial at Johns Hopkins School of Medicine found that two doses of psilocybin, combined with supportive psychotherapy, produced large and rapid reductions in depressive symptoms in adults with major depressive disorder. The effects were four times larger than those typically seen with traditional antidepressants.
Source: Davis AK, Barrett FS, et al. “Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder.” JAMA Psychiatry, 2021.
Johns Hopkins — Effects Last at Least 12 Months (2022)
A follow-up study tracked participants from the original Johns Hopkins depression trial for a full year. At 12 months, 75% of participants still showed a clinical response, and 58% were in full remission from depression — from just one or two psilocybin sessions.
Source: Gukasyan N, Davis AK, et al. “Efficacy and Safety of Psilocybin-Assisted Treatment for Major Depressive Disorder: Prospective 12-Month Follow-Up.” Journal of Psychopharmacology, 2022.
Imperial College London — Psilocybin vs. Antidepressant (2021)
In a head-to-head trial published in the New England Journal of Medicine, two doses of psilocybin were compared with a 6-week course of escitalopram (a leading SSRI antidepressant) in patients with moderate-to-severe depression. Remission rates were 57% in the psilocybin group versus 28% in the escitalopram group. Psilocybin also showed faster onset of antidepressant effects and fewer side effects including less drowsiness, sexual dysfunction, and dry mouth.
Source: Carhart-Harris R, Giribaldi B, et al. “Trial of Psilocybin versus Escitalopram for Depression.” New England Journal of Medicine, 2021.
Licensed healing center space in Denver available for certified facilitators. Private sessions, group journeys & classes. Contact Vivid Minds.
Visit Us:
This website is for educational and informational purposes only. Psilocybin products are not available for sale through this platform. Any product descriptions and related content are provided for reference purposes only.
By using this website, you acknowledge that psilocybin is a regulated substance in Colorado, and access to legal use is limited under state law. Nothing on this website constitutes an offer to sell, medical advice, or legal advice. Please consult applicable state and local laws before engaging in any activities related to psilocybin.